Last reviewed 2026-04-22 · How we verify

carbamazepine ER (Equetro)

Carbamazepine stabilizes neuronal membranes and reduces repetitive neuronal firing by blocking voltage-gated sodium channels.

Carbamazepine stabilizes neuronal membranes and reduces repetitive neuronal firing by blocking voltage-gated sodium channels. Used for Bipolar I disorder, acute mania and mixed episodes, Epilepsy (seizure disorders), Trigeminal neuralgia.

At a glance

Mechanism of action

Carbamazepine acts primarily as a sodium channel blocker, which decreases the influx of sodium ions into neurons and stabilizes the inactive state of the channel. This reduces the frequency of action potentials and neuronal excitability. The extended-release formulation (Equetro) provides sustained drug levels to maintain therapeutic effects with reduced dosing frequency.

Approved indications

• Bipolar I disorder, acute mania and mixed episodes
• Epilepsy (seizure disorders)
• Trigeminal neuralgia
• Neuropathic pain

Common side effects

• Dizziness
• Ataxia
• Somnolence
• Diplopia
• Blurred vision
• Nausea
• Rash (including Stevens-Johnson syndrome risk)
• Hyponatremia
• Agranulocytosis

Key clinical trials

• Equetro for the Treatment of Mania in Children Ages 6-12 With Bipolar Disorder (PHASE4)
• Carbamazepine Extended-Release for the Treatment of Bipolar Depression (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• carbamazepine ER (Equetro) CI brief — competitive landscape report
• carbamazepine ER (Equetro) updates RSS · CI watch RSS
• Massachusetts General Hospital portfolio CI